Breast Cancer Research Opportunities

At Little Pink Houses of Hope, we believe in connecting breast cancer patients with resources and opportunities that may make a difference. As part of that commitment, we are pleased to share research opportunities from trusted, vetted partners who are working to advance our understanding of breast cancer and improve the lives of those affected.

Participation is always voluntary and completely separate from Little Pink’s programs. Choosing to participate—or not participate—in any research opportunity has absolutely no impact on your eligibility, application, or selection for a Little Pink retreat or other program.

Please note: Little Pink’s role is limited to sharing information about these opportunities. We do not conduct or oversee the research, collect or store participant information, or have access to individual responses or study results. All research activities and data management are the responsibility of the organizations conducting the studies.

New Research Opportunity for Women with HER2-Negative Breast Cancer
Opinion Health is currently inviting women in the US to join a new patient registry for HER2-Ultralow breast cancer and they have asked us if we can help with the enrolment of eligible participants over the next 6 months.
Time commitment and Payment
Very limited – participants create a profile, connect their health system or medical records, and that’s it. Once validated as HER2-ultra low, patients receive $150 compensation. They may also be invited to future paid research opportunities as the registry grows.
Did you know that breast cancer classifications have recently changed? If you have been told you are HER2-negative, there is a chance you may fall into a newly recognized subtype called HER2-ultralow, and you might not even know it yet. In fact, research suggests that around 10-20% of HER2-negative patients may qualify as ultra-low. Why not find out?
Participating is simple, and each eligible participant will receive compensation for their time.
Why this matters
Clinical trials don’t always capture the full, real-life patient experience. The aim of the registry is to collect robust and meaningful data to better understand the real-world experiences of women living with this recently recognised subtype and support and inform clinical decision-making. In February 2025 a new therapy was approved for patients with HER2-ultralow breast cancer, making this the first therapy available for patients with this specific type of breast cancer.
If you would like to learn more about the registry and what it entails, please contact Opinion Health by emailing info@opinionhealth.com with “Little Pink 19057” in the subject line.
To register your interest, please use the link below and one of the Opinion Health team will be in touch:
Register for Study